Telehealth startups see an opportunity in chronic disease

Companies are betting that telehealth makes practical sense for patients whose chronic diseases make it hard to get in-person medical care.

April 23, 2024 Check out STAT+

Sponsored By

Molly Ferguson for STAT STAT+ | Telehealth startups see an opportunity in long-ignored, complex chronic diseases Companies are betting that telehealth makes practical sense for patients whose chronic diseases make it hard to get in-person medical care. By Isabella Cueto Trump surrogates hint at how he could reshape U.S. health care policy STAT spoke with people close to Trump's orbit who emphasized his interest in reshaping Medicare's drug pricing policies and taking on ACA markets. By Sarah Owermohle STAT+ | Health care lobbying giants spent big as little got done in Congress Pharmacy benefit managers, for one, spent big on lobbying this spring — and Congress did nothing to rein in how they operate. By Rachel Cohrs Zhang Brandon Bell/Getty Images Opinion: EMTALA, a vital health law you've never heard of, is in danger The Emergency Medical Treatment and Labor Act (EMTALA) guarantees emergency care. A SCOTUS case could begin chipping away at it. By Nicole Huberfeld STAT+ | The evidence grows: Prices spike after mergers between far-flung hospitals A new study shows that cross-market hospital mergers drive up prices, adding to evidence that could aid the FTC in blocking the deals. By Tara Bannow STAT+ | Accreditation agencies take on telehealth with new virtual care standards The Joint Commission, and the National Committee for Quality Assurance will launch updated accreditation programs for telehealth providers. By Katie Palmer Photo Illustration: STAT; Photo: SAUL LOEB/AFP via Getty Images Opinion: Lessons to psychiatrists-in-training from the CIA's mind-control projects The troubling history of the CIA's work with psychiatrists in the 1950s should prompt self-reflection about treatment methods and outcomes. By Casimir Klim STAT+ | Day One drug for common childhood brain tumor approved by FDA Researchers hope the pill, which will be marketed as Ojemda, may allow more patients to reach adulthood without highly toxic treatments such as radiation. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser